Fig. 3
From: PTPRO represses breast cancer lung metastasis by inhibiting the JAK2-YAP axis
PTPRO inactivates the JAK2–YAP pathway. (A) Prediction of the protein interaction network downstream of PTPRO. A protein‒protein interaction network illustrating the interactions between PTPRO and seven PTPRO-associated proteins was constructed using the STING interaction group database (networkhttps://stringdb.org/cgi/network). According to the gene set enrichment analysis, the expression of PTPRO was negatively correlated with that of proteins in the JAK2/STAT and YAP/TAZ pathways (GSE20685; P = 0.002, P < 0.001, respectively; NES, normalized enrichment score). (B) Representative images of immunohistochemistry detection of PTPRO, p-JAK2 (Y1007/Y1008) and p-YAP (Y357) in Ptpro+/+PyMT and Ptpro−/− PyMT mouse mammary tumours (left). Bar charts show the quantification of the staining (right). (C) Representative immunohistochemistry images of PTPRO, p-JAK2 (Y1007/Y1008) and p-YAP (Y357) in the same tumours from two primary human breast cancer samples (left). Percentage of samples showing p-JAK2 (Y1007/Y1008) and p-YAP (Y357) expression relative to the levels of PTPRO in 15 cases of human breast cancer samples (right). (D) Western blotting was used to detect changes in the expression levels of the PTPRO and JAK2–YAP pathways in PTPRO-overexpressing BT474 cells and PTPRO-knockdown ZR75-1 cells. β-actin was used as the internal reference. (E) Co-immunoprecipitation showed interaction between PTPRO, JAK2, and YAP in the ZR75-1 cell line with endogenous high expression of PTPRO. Immunoprecipitation (IP) was performed using anti-PTPRO, anti-JAK2 or anti-YAP antibodies. The error bars indicate the SEM. *P < 0.05, ***P < 0.001, ****P < 0.0001 by Student’s t test (B) or Spearman’s rank test (C).
